Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin
| Autor: | Takao Ozaki, Kohji Ueda, Harumi Kuno-Sakai, Michio Koike, Mizuo Hirose, Hitoshi Kamiya, Shin Isomura, Mikio Kimura, Tatsuo Kato, Tsuneyoshi Egami |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Bordetella pertussis
Filamentous haemagglutinin adhesin Pertussis toxin Microbiology Antigen medicine Humans Prospective Studies Virulence Factors Bordetella Child Diphtheria-Tetanus-Pertussis Vaccine Pertussis Vaccine Reactogenicity biology business.industry Immunogenicity Diphtheria Infant biology.organism_classification medicine.disease Virology Antibodies Bacterial Hemagglutinins Pertussis Toxin Child Preschool Pediatrics Perinatology and Child Health Pertussis vaccine business medicine.drug |
| Zdroj: | Acta paediatrica Japonica : Overseas edition. 37(5) |
| ISSN: | 0374-5600 |
| Popis: | This is the report on a prospective, single blind, comparative study of a component acellular pertussis vaccine produced by a combination of detoxified, column purified pertussis toxin (PT) and filamentous hemagglutinin (FHA) combined with diphtheria and tetanus toxoids (DTcaP) and the traditional acellular pertussis vaccine produced with essentially the same method as described by Sato with DT (DTaP) of the same manufacturer. A total of 616 infants and children received DTcaP and a total of 289 received DTaP. In all age groups for both vaccines values of serum antibodies to PT and FHA after two doses of the vaccines were comparable to those of convalescent sera. Incidences of systemic and local reactions were, in general, not greatly different between DTcaP and DTaP recipients. In Japan the use of traditional acellular vaccines replaced whole cell vaccines in 1981. Protective antigens of Bordetella pertussis have now been specified and thus component vaccines have become theoretically possible. This is the first component vaccine which has been developed in Japan. Several other component vaccines are now under investigation in the world. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text